Delivery Order SPE2DB22D1041-SPE2DB25FUBX9
- Not listed
- The Defense Logistics Agency awarded a $18,664.07 delivery order to AmerisourceBergen Drug Corp for Ondansetron HCL 4 mg tablets (30-count units) with a completion date of September 11, 2025. This competitive award, issued as a firm fixed-price delivery order with no set-aside designation, represents a single transaction under AmerisourceBergen's larger contract vehicle with the agency. The pharmaceutical product will be delivered to the company's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $3,759.95 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets in quantities of 30, with an ultimate completion date of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The product will be performed from the contractor's facility...
- The Defense Logistics Agency awarded a delivery order valued at $3,938.52 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This competitively awarded, firm fixed-price contract is scheduled for completion by August 4, 2025, with performance at the contractor's corporate headquarters in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a continuation of AmerisourceBergen's extensive pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $3,326.60 to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 count). The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award status. Performance is scheduled to conclude by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $14,466.96 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,730.96 to AmerisourceBergen Drug Corp for 500 tablets of Ondansetron HCL 4 mg on August 14, 2025. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, with performance occurring at the contractor's location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified pharmaceutical suppliers. This delivery order...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30 units. This competitively awarded, non-set-aside contract carries a ceiling value of $8,962.67 under a firm fixed price structure, with an ultimate completion date of August 20, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $6,179.85 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This competitively awarded, non-set-aside contract carries a firm fixed price and is scheduled for completion by August 14, 2025. The award will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30, with a ceiling value of $23,438.54. This is a firm fixed price delivery order with no set-aside designation, completed through open competition. The order is scheduled for ultimate completion by September 2, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls...
- The Defense Logistics Agency awarded a delivery order valued at $18,060.83 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (500-count units). This firm fixed-price delivery order, awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical vendor...
- SPE2DB22D1041Indefinite Delivery Contract
- SPE2DB22D1041-SPE2DB25FUBX9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,651.47 to AmerisourceBergen Drug Corp for the supply of Ondansetron HCL 4 mg tablets (30 count) on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed-price, non-set-aside contract with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of the company's critical role as a pharmaceutical distributor supporting federal medical procurement needs. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Ondansetron, an anti-nausea medication commonly used in healthcare settings, exemplifies the company's role in delivering essential pharmaceutical commodities to the Defense Health Agency and other federal healthcare systems. AmerisourceBergen has consistently demonstrated its capability to meet federal procurement requirements through competitive awards across multiple therapeutic domains, supporting the military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 9/9/25 |